Spots Global Cancer Trial Database for trametinib dimethyl sulfoxide
Every month we try and update this database with for trametinib dimethyl sulfoxide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | NCT04439318 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | NCT01902173 | Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | NCT04557956 | Clinical Stage ... Metastatic Mela... | Biopsy Computed Tomogr... Dabrafenib Mesy... Echocardiogram ... Magnetic Resona... Multigated Acqu... Tazemetostat Hy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | NCT04439357 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | NCT04527549 | Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me... | Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime... | 18 Years - | Eastern Cooperative Oncology Group | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | NCT04439279 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | NCT02224781 | Clinical Stage ... Clinical Stage ... Metastatic Mela... Recurrent Melan... Unresectable Me... | Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Echocardiograph... Ipilimumab Multigated Acqu... Nivolumab Quality-of-Life... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | NCT04439292 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Dabrafenib Mesy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | NCT04527549 | Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me... | Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime... | 18 Years - | Eastern Cooperative Oncology Group | |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) | NCT04439292 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Dabrafenib Mesy... Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | NCT02101788 | Borderline Ovar... Micropapillary ... Ovarian Serous ... Primary Periton... Recurrent Ovari... Recurrent Prima... | Letrozole Paclitaxel Pegylated Lipos... Quality-of-Life... Questionnaire A... Tamoxifen Citra... Topotecan Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | NCT03919071 | Anaplastic Astr... Anaplastic Astr... Anaplastic Gang... Anaplastic Pleo... Glioblastoma Malignant Gliom... WHO Grade 3 Gli... | Biospecimen Col... Dabrafenib Mesy... Lumbar Puncture Magnetic Resona... Radiation Thera... Trametinib Dime... | 12 Months - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
